| IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2 C Jackaman, CS Bundell, BF Kinnear, AM Smith, P Filion, D van Hagen, ... The Journal of Immunology 171 (10), 5051-5063, 2003 | 241 | 2003 |
| A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma AK Nowak, AM Cook, AM McDonnell, MJ Millward, J Creaney, RJ Francis, ... Annals of Oncology 26 (12), 2483-2490, 2015 | 94 | 2015 |
| Tumor‐infiltrating dendritic cells exhibit defective cross‐presentation of tumor antigens, but is reversed by chemotherapy AM McDonnell, WJ Lesterhuis, A Khong, AK Nowak, RA Lake, AJ Currie, ... European journal of immunology 45 (1), 49-59, 2015 | 86 | 2015 |
| Tumor antigen cross-presentation and the dendritic cell: where it all begins? AM McDonnell, BWS Robinson, AJ Currie Journal of Immunology Research 2010, 2010 | 85 | 2010 |
| Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation AJ Currie, A Prosser, A McDonnell, AL Cleaver, BWS Robinson, ... The Journal of Immunology 183 (12), 7898-7908, 2009 | 74 | 2009 |
| Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies AM Cook, AM McDonnell, RA Lake, AK Nowak Oncoimmunology 5 (3), e1066062, 2016 | 71 | 2016 |
| CD8á+ DC are not the sole subset cross‐presenting cell‐associated tumor antigens from a solid tumor AM McDonnell, AC Prosser, I Van Bruggen, BWS Robinson, AJ Currie European journal of immunology 40 (6), 1617-1627, 2010 | 55 | 2010 |
| Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy N Principe, J Kidman, S Goh, CM Tilsed, SA Fisher, VS Fear, CA Forbes, ... Frontiers in Immunology 11, 584423, 2020 | 52 | 2020 |
| Contribution of the immune system to the chemotherapeutic response AM McDonnell, AK Nowak, RA Lake Seminars in immunopathology 33, 353-367, 2011 | 39 | 2011 |
| Cross-Presenting XCR1+ Dendritic Cells as Targets for Cancer Immunotherapy KM Audsley, AM McDonnell, J Waithman Cells 9 (3), 565, 2020 | 36 | 2020 |
| PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors TM Meniawy, RA Lake, AM McDonnell, MJ Millward, AK Nowak Lung Cancer 93, 9-16, 2016 | 33 | 2016 |
| Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation AM McDonnell, AJ Currie, M Brown, K Kania, B Wylie, A Cleaver, R Lake, ... Oncoimmunology 1, 840-846, 2012 | 33 | 2012 |
| Immune checkpoint inhibition for the treatment of mesothelioma AK Nowak, A McDonnell, A Cook Expert Opinion on Biological Therapy 19 (7), 697-706, 2019 | 23 | 2019 |
| Restoration of defective cross-presentation in tumors by gemcitabine AM McDonnell, W Joost Lesterhuis, A Khong, AK Nowak, RA Lake, ... Oncoimmunology 4 (5), e1005501, 2015 | 21 | 2015 |
| Fine-tuning the tumour microenvironment: current perspectives on the mechanisms of tumour immunosuppression JD Armitage, HV Newnes, A McDonnell, A Bosco, J Waithman Cells 10 (1), 56, 2021 | 20 | 2021 |
| Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors SJ Dart, AM Cook, MJ Millward, AM McDonnell, WL Chin, MU Hakeem, ... Scientific Reports 11 (1), 15312, 2021 | 16 | 2021 |
| Malignant pleural effusions—a window into local anti-tumor T cell immunity? N Principe, J Kidman, RA Lake, WJ Lesterhuis, AK Nowak, AM McDonnell, ... Frontiers in Oncology 11, 672747, 2021 | 14 | 2021 |
| IFNâ is a potent adjuvant for cancer vaccination strategies KM Audsley, T Wagner, C Ta, HV Newnes, AC Buzzai, SA Barnes, ... Frontiers in Immunology 12, 735133, 2021 | 12 | 2021 |
| Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors J Chee, MW Watson, A Chopra, B Nguyen, AM Cook, J Creaney, ... BMC research notes 11, 1-6, 2018 | 10 | 2018 |
| Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell … AM McDonnell, A Cook, BWS Robinson, RA Lake, AK Nowak BMC cancer 17, 1-15, 2017 | 9 | 2017 |
Bruce Robinsonuniversity of western austRALIAVerified email at uwa.edu.au
